

**The Edward P. Evans Foundation  
MDS Research Summit  
Sept. 20, 2014  
Sheraton Hotel, Philadelphia PA**

**Agenda**

- 8:00 – 9:00 Breakfast
- 9:00- 9:05 Welcome, Michael Lewis, President of the Edward P. Evans Foundation
- 9:05-9:25 Ben Ebert “Mechanism of action of Lenalidomide in 5q MDS”
- 9:25-9:45 Omar Abdel-Wahab – “SRSF2 mutations impair hematopoiesis through alterations in exon-specific enhancer recognition” and Eric Padron “Molecular characterization of SRSF2 mutation identifies a clinically relevant lncRNA in CMML”
- 9:45-10:05 Tim Graubert and Matt Walter “U2AF1”
- 10:05-10:20 Stephanie Halene, “Mutations in SRSF2 affect RNA binding affinity, specificity, and splicing events”
- 10:20-10:35 Clara Kielkopf “Pre-mRNA splice site signal recognition by U2AF1, a frequently mutated factor in MDS”
- 10:35-10:50 Melanie Ohi, “CryoEM analysis of the spliceosome”
- 10:50-11:10 Break—begin discussions informally
- 11:10-11:25 Discussion of Innovative ways to attack MDS
- 11:25-11:40 Dan Starczynowski, "Novel mechanism of HSC regulation by TRAF6 in MDS"
- 11:40-12:00 Sandy Zinkel, "Necroptosis signaling in bone marrow failure in MDS"
- 12:00-12:20** Guillermo Garcia-Manero “Clinical Research Consortium”
- 12:20-1:30** Working lunch to form collaborative relationships
- 1:30-1:50** Michelle LeBeau, “Synergistic Interaction of the Microenvironment with del(5q) MDS Stem Cells”
- 1:50-2:10** Hartmut Geiger, “t-MDS predisposition factors”
- 2:10-2:30** Martin Carroll, “Mouse xenograft models of MDS”
- 2:30-2:50** Ken Figuero and Steve Gore “Specific molecular signatures underlie response to Decitabine in CMML”
- 2:50-3:10** Ari Melnick, “The epigenomic basis of relapsing myeloid malignancy”
- 3:10-3:30** David Steensma “The challenge of translating scientific discovery into clinical advances in MDS”
- 3:30-4:00** Discussion of Innovative ways to attack MDS and Future Directions
- 4:00** Reception and continuation of collaborative interactions